Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lamivudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 3/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 2/20 | 1.00 |
| ▸ | CACNA1S | Q13698 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | POLG | P54098 | 3/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.52 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.52 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lamivudine SCHEMBL109675 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL33979 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12964486 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2305925 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2422788 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2240686 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL12996723 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL465678 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL2806818 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT | |
| Lamivudine SCHEMBL13006083 | 1.00 | ALB (1.00) | ALBLMNAPDE3ACACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | claimed |
| US-20130296562-A1 | STEREOSELECTIVE PROCESS FOR PREPARATION OF 1,3-OXATHIOLANE NUCLEOSIDES | LUPIN LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-20110245497-A1 | OPTICAL RESOLUTION OF SUBSTITUTED 1, 3-OXATHIOLANE NUCLEOSIDES | HETERO RESEARCH FOUNDATION (IN) | 2011-10-06 | — | — | US | disclosed |
| US-20110245497-A1 | OPTICAL RESOLUTION OF SUBSTITUTED 1, 3-OXATHIOLANE NUCLEOSIDES | HETERO RESEARCH FOUNDATION (IN) | 2011-10-06 | — | — | US | disclosed |
| US-20100311961-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 1,3-OXATHIOLANES, ESPECIALLY LAMIVUDINE | RANBAXY LABORATORIES LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| WO-2010067375-A2 | OPTICAL RESOLUTION OF SUBSTITUTED 1.3-OXATHIOLANE NUCLEOSIDES | HETERO RESEARCH FOUNDATION (IN) | 2010-06-17 | — | — | WO | disclosed |
| US-20070218486-A1 | Immunoassays, Haptens, Immunogens and Antibodies for Anti-HIV Therapeutics | ARK DIAGNOSTICS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070218486-A1 | Immunoassays, Haptens, Immunogens and Antibodies for Anti-HIV Therapeutics | ARK DIAGNOSTICS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007103740-A2 | IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS | ARK DIAGNOSTICS (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | PYGL, ALPI, SLC10A1 | ALB 2647/4885LMNA 3305/4885PDE3A 446/4885 |
| US-20130296562-A1 | STEREOSELECTIVE PROCESS FOR PREPARATION OF 1,3-OXATHIOLANE NUCLEOSIDES | TYMS, SAMHD1, TYMP | ALB 4069/4885LMNA 3679/4885PDE3A 3650/4885 |
| US-20100311961-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF SUBSTITUTED 1,3-OXATHIOLANES, ESPECIALLY LAMIVUDINE | TYMP, TYMS, NUDT1 | ALB 4267/4885LMNA 969/4885PDE3A 1668/4885 |
| US-20110245497-A1 | OPTICAL RESOLUTION OF SUBSTITUTED 1, 3-OXATHIOLANE NUCLEOSIDES | NUDT1, PNP, TYMP | ALB 1577/4885LMNA 2653/4885PDE3A 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.